Skip to main content

Market Overview

UPDATE: Deutsche Bank Initiates Coverage On Merck

Share:

Deutsche Bank initiated coverage of Merck (NYSE: MRK) with a Hold rating and price target of $63.

Analyst Gregg Gilbert outlined reasons for the initiation:

  • Merck has established base businesses, with a track record of returning cash to shareholders.
  • Merck has potential multi-billion dollar products in the pipeline awaiting completion of later stages of phase two and three trials.
  • Merck is becoming well-positioned in the Hepatitis C (HVC) space with recent acquisition of Idenix (NASDAQ: IDIX). Gilbert stated,”Merck could differentiate itself with a product that is easier to use and has shorter treatment duration to gain market share.”

Analysts indicate upside risk will come from higher-than-expected peak sales for pembro and its HCV franchise.

Downside risks include approval delay for pembrolizumab in advanced melanoma or negative data from the C-SWIFT trial for HCV genotypes.

Latest Ratings for MRK

DateFirmActionFromTo
Nov 2020BernsteinReinstatesOutperform
Oct 2020SVB LeerinkMaintainsOutperform
Oct 2020Truist SecuritiesInitiates Coverage OnBuy

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!

Posted-In: Deutsche Bank Gregg GilbertAnalyst Color Health Care Initiation Analyst Ratings General

Latest Ratings

StockFirmActionPT
IMCRGoldman SachsInitiates Coverage On40.0
RCELPiper SandlerInitiates Coverage On27.0
THNPFExane BNP ParibasInitiates Coverage On
STWRYBarclaysDowngrades
ATNXTruist SecuritiesDowngrades6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com